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BARZAGHI ET AL 1037Background: Immunodysregulation polyendocrinopathy
enteropathyx-linked(IPEX) syndrome is amonogenic autoimmune
disease caused byFOXP3mutations. Because it is a rare disease, the
natural history and response to treatments, including allogeneic
hematopoietic stem cell transplantation (HSCT) and
immunosuppression (IS), have not been thoroughly examined.
Objective: This analysis sought to evaluate disease onset,
progression, and long-term outcome of the 2 main treatments in
long-term IPEX survivors.
Methods: Clinical histories of 96 patients with a genetically
proven IPEX syndrome were collected from 38 institutions
worldwide and retrospectively analyzed. To investigate possible
factors suitable to predict the outcome, an organ involvement
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The immunodysregulation-polyendocrinopathy-enteropathy
x-linked (IPEX) syndrome is a primary immunodeficiency caused
by hemizygous mutations in the gene FOXP3, which encodes an
essential transcription factor required for maintenance of
immunologic tolerance by thymus-derived regulatory T (Treg)
cells. Since its first clinical description in 19821 and its genetic
characterization in 2001,2,3 IPEX syndrome has gathered the
attention of scientists and physicians as the prototype of a
monogenic autoimmune disease and immune deficiency
affecting the immune regulatory compartment.4,5 Significant
advances have been made in elucidating the complex disease
pathogenesis.6-9 The typical manifestations of severe
enteropathy, type 1 diabetes (T1D) and eczema have been
extensively reported, but IPEX still poses a significant
therapeutic challenge. Single reports of young adults affected
by ‘‘atypical’’ or ‘‘late onset’’ IPEX forms have suggested
heterogeneity in both the clinical presentation and their response
to therapy.10-12 Immunosuppressive therapy, the first-line
treatment for IPEX patients, has changed considerably in recent
years with the introduction of new drugs with an immune
suppressive and modulatory action. Nevertheless, the use and
efficacy of these therapies are largely undocumented in IPEX
patients. Currently, the only potentially curative therapy for
IPEX syndrome is allogeneic hematopoietic stem cell
transplantation (HSCT) with the longest published follow-up of
8 years.13,14 Both HLA-identical and matched-unrelated HSCT
can be successful. However, while there is a general
understanding to treat early, a comprehensive study comparing
different transplant protocols and long-term outcomes is not
available. In addition, a significant number of patients cannot
undergo HSCT, due to limited donor availability and high
risk-benefit ratio. Finally, older patients with a mild disease
phenotype, in whom the clinical manifestations are often not
severe enough to justify HSCT, raise concerns regarding the
appropriate treatment.15
This international multicenter retrospective analysis of IPEX
patients aims to provide a comprehensive view of the disease, its
evolution, and outcomes of different therapeutic strategies. We
aim to unveil limitations of case reports or small case series by
providing a more comprehensive analysis of a large patients’
cohort. Ultimately, our work aims to improve the diagnosis and
the long-term treatment for IPEX syndrome, with the goal of
achieving definitive cure, which could apply to other
immunodeficiencies with autoimmunity.METHODS
Patients’ cohort and definitions
A retrospective multicenter study was performed in which data were
collected from 38 institutions worldwide. All patients included were
diagnosed with IPEX syndrome based on the presence of a FOXP3
mutation (detected but not specified for 5 patients). Data were collected
through a detailed survey. Each center notified to their institutional reviewboard and, if required, obtained the approval for sharing the data included
in the present study. Data were transferred in a completely deidentified
form.
Clinical manifestations were defined as ‘‘autoimmune’’ based on
exclusion of other causes, the presence of specific autoantibodies or
presence of other pathological findings suggestive of autoimmune
etiology, or ex juvantibus (positive response to immunosuppressive
therapy). Based on the number of organs or systems impaired by the
autoimmune damage or by secondary complications, before
undergoing immunosuppression (IS) or HSCT, we established an organ
involvement (OI) scoring system ranging between 0 and 5; 1 point was
assigned for the presence of each of the following: intractable diarrhea,
malnutrition, liver dysfunction, respiratory impairment, kidney
dysfunction. The selection of these parameters was dictated by their
relevance in affecting disease morbidity and survival. The presence
of clinical manifestations was assessed by the caring physicians,
according to standard of care definitions.
The effect of ISwas considered ‘‘beneficial’’ when the physician observed a
decrease (partial benefit) or complete disappearance (benefit) of signs and
symptoms of the disease.
Conditioning regimens were defined as fully myeloablative (full) or as
reduced intensity transplant (RIT). Full conditioning regimens included
busulfan plus cyclophosphamide, busulfan of > 14 mg/kg or cumulative
area under the curve of 80 to 90mg3 h/L (when available) plus fludarabine, or
treosulfan. RIT encompassed both reduced intensity conditioning
(eg, fludarabine plus nonmyeloablative doses of busulfan, treosulfan, or
melphalan) and minimal intensity conditioning (eg, fludarabine plus low dose
radiation or cyclophosphamide).16
Neutrophil engraftment was defined as the first of 3 consecutive days with
neutrophils >1000 per mm3 unsupported; platelet engraftment was defined as
the first of 3 days with platelets >50,000 per mm3 unsupported. A ‘‘boost’’ was
an additional infusion of HSC without conditioning, while ‘‘second or third’’
transplants were additional infusions of HSC from a different donor with
conditioning. T-cell reconstitution (analyzed at 3, 6, and 12 months and at
the last available follow-up) was defined as >1000 CD31 T cells per mm3,
>500 CD41 T cells per mm3 and presence of proliferative response to
mitogens (considered as positive when within the normal range of the
laboratory). B-cell reconstitution was defined as independence from
immunoglobulin replacement therapy. Full conditioning regimen donor
chimerism was defined as >95% donor cells in peripheral blood (evaluated
at 3, 6, and 12 months and at last follow-up). Primary graft failure was defined
as absence of donor cells in peripheral blood posttransplant. Secondary graft
failure was defined as reduction of neutrophil counts, occurring after
engraftment, and absence of donor cells (below 5%), despite normal blood
counts. The diagnosis and grading of acute or chronic graft-versus-host
disease (GvHD) were based on previously published criteria and scoring
system.17
Evaluation of quality of lifewas reported by the caring physicians without a
standardized scoring system (yes/no questions).
FIG 1. Patients’ demographics and disease-related characteristics. A, Diagnostic delay scatter plot
displaying correlation between age at diagnosis and age at onset (n 5 96). Spearman’s rank correlation
r 5 0.456, P < .001. B, Histogram distribution of number of patients diagnosed between 2001 and 2015.
Overlaid density distribution showed in blue. C, Heat map of number of symptoms at onset grouped by
age at onset. Symptoms present in each age group (indicated by rows) were scaled (z-score or standardized
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Demographic, disease-related, or transplant-related characteristics were
reported as frequencies for categorical variables, and median and range for
quantitative variables. Associations between variables and disease outcome or
type of treatment were compared with the use of the chi-square test
(categorical variables) or unpaired t-test (continuous variables).
Probabilities of survival after treatment and disease-free survival (DFS)
were computed with the use of the Kaplan-Meier estimator and compared with
the log-rank test (Mantel-Cox). We then used a multivariable analysis to
examine risk factors for transplantation outcomes and adjust for confounding
factors using the Cox (proportional hazard) regression models with Breslow
estimator; a P value of .05 or less was considered statistically significant. The
variables considered in the Cox regression to model transplantation outcome
were age at transplant, pre-HSCT OI score, donor type, degree of
HLA-matching, intensity of conditioning regimen, graft source, and number
of CD34 cells infused. For a small cohort of patients transplanted at
<1 year, the variables used in the Cox regression were age at HSCT, score,
and weight.We also examined DFS with a Cox regression model, where death
is treated as a censoring event, using as predictor variables the score
pre-HSCT, graft failure, and conditioning.
The patients whose mutations were known (n 5 91) were grouped in 4
categories depending on type of mutation: missense, splice site, frameshift or
in-frame deletions or insertions; and ‘‘others’’ including mutations in the
untranslated region, promoter, or start codon. We furthermore explored each
mutation effect on protein function through available algorithms such as
PolyPhen-2 (providing predictions for amino acid substitutions) and
PROVEAN (providing predictions for amino acid substitutions, insertions,
and deletions), obtaining a numeric score and a qualitative prediction outcome
such as ‘‘benign’’ or ‘‘neutral,’’ and ‘‘deleterious’’ or ‘‘probably damaging.’’
We examined associations among the predicted protein scores and each
patient score before HSCT or IS and their survival outcome, by evaluating
Spearman correlation coefficient and contingency tables.RESULTS
Initial clinical manifestations, disease course, and
genetics
Ninety-six patients with FOXP3 mutations were included in
our study. The median age at disease onset was 2 months (range,
birth to 11.3 years): 41% had onset within the first month of life,
46% between 1 month and 1 year, 10% after 1 year of age, and for
3% of patients, the time of onset was unavailable. The median
time to diagnosis (elapsed time between onset of symptoms and
genetic diagnosis)was 14months (up to amaximumof 23.9 years)
(Fig 1, A); however, the number of IPEX patients diagnosed per
year shows an increased trend (Fig 1, B).
The most common presentation suggestive of the diagnosis of
IPEX syndrome remained the classical triad of enteropathy, T1D,
and eczema for the majority of the 39 of 96 patients who had
neonatal onset. Gastrointestinal involvement and eczema, but notscore) and then converted to colors from yellow (low 5
were not available (NA) for 3 patients; 1 patient has the
for 2 patients, the first symptom is unknown. D, Bar gra
later during disease evolution. Every bar indicates num
each patient can exhibit >1 symptom at once. E, Uncom
patients presenting each symptom. F, Scatter plot of FO
age at onset (circles) and number of symptoms at ons
cDNA FOXP3mutations were not specified). Gene struc
zinc-finger (ZF) domain (green), leucine-zipper (LZ) dom
(red). Mutations were grouped as follows: <c.1 to c.57
E5-6 ZF domain, <c.717 to c.780> 5 E6-7 LZ domain
<c.1011 to c.1251> 5 E9-11 FKH domain. AIHA, Au
neutropenia; AT, autoimmune thyroiditis; FTT, failure t
Neph, nephropathy; LN, lymphadenopathy; PRR, prolinT1D, were the dominant features of disease presentation after
1 month of age. However, failure to thrive was a hallmark of the
disease and it was sometimes the sole initial manifestation after
1 month of age. After 1 year of age, the disease could also present
with nephropathy or hepatitis, otherwise considered atypical at
onset (Fig 1, C and D).
The symptoms observed over the course of the disease and their
prevalence are listed (Fig 1, D): with the exception of diarrhea,
eczema, and failure to thrive, nephropathy (autoimmune or
secondary to malnutrition and medication) was the most common
(33 of 96 patients), varying from lithiasis, nephrocalcinosis, or
isolated proteinuria to more severe manifestations such as
nephrotic syndrome (in some cases with a definite diagnosis of
glomerulonephritis) or tubulopathy and interstitial nephritis.
Hematological manifestations included autoimmune
hemolytic anemia (25 of 96 patients), thrombocytopenia (13 of
96 patients), and neutropenia (6 of 96 patients). Other conditions
included autoimmune thyroiditis (15 of 96 patients) and
hepatitis (19 of 96 patients), while food allergies (13 of 96
patients), arthritis (8 of 96 patients), alopecia (8 of 96 patients),
and lymphadenopathy (9 of 96 patients) were occasionally
reported during disease progression. Interestingly, among other
uncommon manifestations (Fig 1, E), neurological findings, of
uncertain relation with FOXP3 mutations, were reported in
16 of 96 patients, including peripheral neuropathy, myopathies/
hypotonia, hemidiaphragmatic paralysis, eosinophilic meningi-
tis, neurodevelopmental delay, seizures, and benign intracranial
hypertension.
The 96 patients included in the study displayed 33 published
mutations4,5 and 21 novel mutations. The forkhead (FKH)
domain emerges as a mutational hotspot of the FOXP3 gene
(Fig 1, F), although mutations were scattered along the gene.
Mutations in the N-terminal and FKH domains correlated with
high variability of age at onset. The number of symptoms at onset
was independent from the site of the mutations.Laboratory findings
Table I summarizes the biological findings characterizing this
IPEX patients’ cohort before therapy. The distribution of
lymphocyte subsets before IS or in patients treated with
long-lasting IS or before HSCT was normal or seldom
characterized by increased counts. The proportion of Treg cells,
evaluated by flow cytometry, was available only in few patients
and FOXP3 showed a wide range of expression. Gut biopsies
frequently showed simultaneous involvement of several sites:
the most common target was the small bowel, followed by largeless frequent) to red (high 5 highly frequent). Data
mutation but has not yet experienced the onset; and
ph comparing frequency of symptoms at onset and
ber of patients presenting each symptom. However,
mon manifestations. Every bar indicates number of
XP3 gene mutations grouped by domain, indicating
et (asterisks), with median (n 5 87; for 10 patients,
ture: N-terminal proline-rich (PRR) domain (orange),
ain (blue), LZ-FKH loop (yellow), and FKH domain
0> 5 E1-5 N-terminal domain, <c.591 to c.666> 5
, <c.781 to c.1010> 5 E7-9 LZ-FKH loop domain,
toimmune hemolytic anemia; AIN, autoimmune
o thrive; ITP, idiopathic thrombocytopenic purpura;
e-rich region; UTR, untranslated region.
TABLE I. Biological findings characterizing the IPEX patients’
cohort before therapy
Immunophenotype pre-IS
Median; range
(no. Of patients tested)
Lymph tot/mmc 2925; 900-7480 (22)
CD3+/mmc 2047; 600-4838 (23)
CD3+CD4+/mmc 1276; 370-3658 (24)
CD3+CD8+/mmc 586; 210-2020 (23)
Ratio CD4:CD8 2; 0.5-3.9 (23)
CD19+/mmc 276; 0-1715 (22)
CD16+CD56+/mmc 170; 20-525 (21)
CD4+CD25+, % 9; 0-35 (10)
CD4+CD25+CD127low, % 3; 1-6.6 (5)
FOXP3+, % in CD4+CD25+CD127low 36; 2.2-58 (5)
FOXP31, % in CD41 5; 0.8-7 (4)
Immunophenotype pre-HSCT
Lymph tot/mmc 3350; 440-8189 (39)
CD3+/mmc 2185; 350-9388 (52)
CD3+CD4+/mmc 1311; 150-7824 (52)
CD3+CD8+/mmc 781; 106-2612 (51)
Ratio CD4:CD8 1.9; 0.3-10.1 (51)
CD19+/mmc 572; 0-6245 (51)
CD16+CD56+/mmc 200; 0-1112 (45)
CD4+CD25+, % 13; 0-49 (18)
CD4+CD25+CD127low, % 7.8; 3.3-20.2 (4)
FOXP3+, % in CD4+CD25+CD127low 50; 1.3-98 (9)
FOXP3+, % in CD4+ 0; 0-5 (3)
Gut biopsies before therapy (tot n 5 61) No. of cases
Number of sites involved
Single 26
Multiple 34
Affected sites
Esophagus 7
Stomach 16
Small bowel 45
Large bowel 16
All sites 7
Combinations of affected sites
Small and large bowel 11
Stomach + small bowel 9
Stomach + large bowel 1
Esophagus + stomach 1
Esophagus + small bowel 2
Stomach + small and large bowel 2
Esophagus + stomach + small bowel 1
Esophagus + small and large bowel 1
Infiltrating cell type
Eosinophils 19
Lymphocytes 32
Plasma cells 8
Polymorphonucleated cells 6
Polymorphic infiltrate including all cells 8
Unspecified inflammatory cell type 4
Histological lesions
Villous atrophy 42
Loss of goblet cells 3
Crypt hyperplasia 9
Crypt abscesses 8
Ulcers 9
(Continued)
TABLE I. (Continued)
Gut biopsies before therapy (tot n 5 61) No. of cases
Loss of parietal cells 2
Metaplasia 4
Enteropathy-related autoantibodies
No. positive/No.
of cases tested
Antienterocyte Abs 25/34
HAA 13/24
Antienterocyte and HAA 4/5
VAA 1/12
Other autoantibodies before
therapy
Tot no of patients tested for GAD 41
GAD among pts with T1D 15/18
GAD among pts without T1D 9/23
Tot no. of patients tested for IA 27
IA among pts with T1D 9/15
IA among pts without T1D 0/12
Tot no. of patients tested for IAA 33
IAA among pts with T1D 10/13
IAA among pts without T1D 3/20
Tot no. of patients tested for ZNT8 14
ZNT8 among pts with T1D 1/8
ZNT8 among pts without T1D 0/6
Tot no. of patients tested for ICA 6
ICA among pts with T1D 1/3
ICA among pts without T1D 3/3
GAD, Glutamic acid decarboxylase autoantibodies; HAA, antiharmonin
autoantibodies; IA, islet antigen; IAA, anti-insulin autoantibodies; ICA, anti-islet cell
antibodies; mmc, mm3; pts, patients; tot, total; VAA, antivillin autoantibodies; ZNT8,
zinc transporter 8 autoantibodies.
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were usually polymorphic with predominance of lymphocytes
and eosinophils. Villous atrophy remained the hallmark of
IPEX enteropathy, although other nonspecific lesions associated
with inflammatory damage (ulcers, crypt hyperplasia, and
abscesses) were present. Of note, 4 patients showed metaplastic
lesions, either in the bowel or in the stomach, and 1 developed
dysplastic lesions of the gastric mucosa. Antienterocyte,
antiharmonin, or antivillin autoantibodies were positive in 33 of
42 patients with enteropathy tested (Table I). In contrast, in 9 of
42 cases these autoantibodies could not be detected despite the
presence of enteropathy, a finding possibly dependent on the
choice of antibodies that were tested. Remarkably, in 1 case,
antiharmonin autoantibody positivity prompted the diagnosis in
a patient with isolated IPEX-related gastritis. Antineuron
antibodies were detected in 1 of the patients with neurological
involvement. Finally, 12 patients screened positive for
T1D-associated autoantibodies (2 of them had 2 positive auto-
antibodies), without having T1D (Table I). Thus, the histological
and serological markers were indicative of the diagnosis only
when considered together with the clinical manifestations.Treatments
Of the 96 patients included in the study, 34 received IS and
58 underwent HSCT. Four patients with FOXP3 mutations
improved spontaneously (1), did not require IS (2), or were still
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FIG 2. Timeline of natural history and disease evolution. Patients undergoing HSCT (A) and IS (B). Each line
represents a patient identified by his FOXP3 mutation in order of localization on the gene. The end on the
line represents the last day of follow-up, and different symbols represent age at onset (circles) and age at
HSCT (triangles) or the beginning of IS. An X at the end of the line indicates the age of death. The color
of the line indicates the disease status after treatment, whether the patient went into remission (blue),
was still diabetic (gray) or not cured (red). NA, Not available.
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FIG 3. Immunosuppressive therapy. A, Bar graph indicating numbers of patients exhibiting response, partial
benefit, or no response according to a specific immunosuppressive drug administered (n5 34; however, each
patient received >1 drug).B,Bar graph indicating each patient’s outcomeafter treatmentwith a combination of
drugs, as last treatment. Each bar represents the number of patients receiving the treatment, distinguishing
those in remission from thosewith additional or persistent autoimmunity (n5 34).C,Pre- and post-IS patients’
conditions, each bar represents the number of patients presenting each condition. On the right side, the rela-
tive percentage is reported (n5 34; however, each patient could present with >1 condition at once).D, Percent-
age of survival for patients undergoing IS (n 5 34) according to score post-IS (P 5 .0444). AZA, Azathioprine;
Ca Inhib, calcineurin inhibitors; CTLA, cytotoxic T lymphocyte–associated antigen;MTX, methotrexate;MMF,
mycophenolate mofetil; ‘‘others’’, any different IS (eg, 6-mercaptopurina, mesalazine); RAPA, rapamycin.
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One patient had several manifestations of the disease
(enteropathy, growth retardation, eczema, autoimmune cytopenia)
that improved spontaneously, with supportive therapy and without
any immunosuppressive drugs. Two other patients had persistent
signs of the disease that, however, did not require IS
(eczema and growth retardation in 1 case and T1D in the other).
The last patient is still asymptomatic at 6 years of age, and he
was diagnosed only due to familial history. Fig 2 provides a
schematic view of the disease evolution of each patient and his
mutation and reveals the variability of disease progression in our
cohort.Immunosuppressive therapy
The 34 patients who received IS and were not transplanted
started treatment at a median age of 1.5 years (range,
1 month-19.6 years) with a median follow-up of 4 years (range,
1 month-25 years). Only 3 patients had a follow-up shorter than
7 months.
Fig 3 shows the response to each drug, to drug combinations,
and the final outcome after IS. Twenty-five patients received
systemic steroids (range, 2 months-22 years; median, 2 years).
While steroid administration benefited 56% of the treated
patients, it was often administered concomitantly with other
immunosuppressive drugs (Fig 3, B), thus direct effects cannot
be confirmed.
Twenty patients received calcineurin inhibitors, either
cyclosporine-A or tacrolimus, with benefit in 40% (Fig 3, A).
Six of them also received concomitant steroids and 3 both steroids
and noncalcineurin inhibitors. Among patients treated with
noncalcineurin inhibitors, 15 patients received rapamycin and
19 received other immunosuppressive agents comprising
azathioprine, methotrexate, mycophenolate-mofetil, mesalazine,
sulfasalazine, and 6-mercaptopurine. Combination of steroids
with calcineurin inhibitor, noncalcineurin inhibitors, or both (12
of 21 patients) infrequently (1 of 12 patients) led to remission
of autoimmunity (Fig 3, B). Rapamycin improved autoimmune
manifestations in 67% of patients (Fig 3,A) and in 8 of 10 patients
when it was used as monotherapy, with 6 of 8 patients achieving
remission (Fig 3, B). The use of azathioprine was beneficial in
36% of cases (Fig 3, A). The use of mAbs, including anti-TNF-
a, anti-CD20, and cytotoxic T lymphocyte–associated antigen 4
fusion protein (abatacept), was usually in addition to other IS;
therefore, their efficacy as single drugs is not fully evaluable.
Although treatment with a mAb was beneficial in the 52% of
cases (Fig 3, A), mAb-based regimens rarely resulted in sustained
remission of autoimmunity (2 of 8 patients) (Fig 3, B).
Prior to initiation of IS, 25 of 34 patients were malnourished
(74%) and 26 of 34 had intractable diarrhea (76%). The prevalence
of these clinical manifestations significantly diminished following
IS, since malnutrition persisted in 10 cases (29%; P < .001) while
diarrhea persisted in 7 cases (20%; P < .001). Similarly, 3 of 5
patients with autoimmune hepatitis improved after IS.
Nevertheless, prevalence of respiratory impairment, kidney
dysfunction and frequency of infections increased under IS
although not significantly (P 5 .538, P 5 .511, and P 5 .627)
(Fig 3, C).
Overall, 10 of 34 patients receiving IS completely controlled
autoimmunity, while 24 patients still had autoimmune
manifestations, mainly enteropathy (11 of 24). T1D remained theonly autoimmune manifestation in 2 patients. In 11 patients new
autoimmune manifestations arose while receiving IS, including
T1D (4), thyroiditis (3), autoimmune cytopenia (2), autoimmune
hepatitis (2), enteropathy (1), adrenal insufficiency (1), and arthritis
(1). Overall, the OI score before starting ISmostly corresponded to
the OI score at disease onset and did not significantly influence the
outcome. Indeed, most of the patients improved in the short term;
whereas in the long term, the OI score could worsen due to disease
recurrence or progression and side effects of treatment, thus
impacting survival (Fig 3, D), as discussed below.
Nutritional support (enteral, parenteral, or both) was often
necessary for patients under IS (19 of 34), lasting for months or
years. Recurrent hospitalization for disease complications and
infections occurred a median of 4 times per year (ranging from
0 to 7 times per year). Thirty of 34 patients are alive at the last
follow-up. Four patients died (at 5 months, and 1.5, 7, and
22.5 years, respectively). Causes of death were acute respiratory
distress syndrome with multiple organ failure, pneumonia,
idiopathic cardiac arrest, and sepsis. The estimated overall
survival of patients under IS was 86.8% (95% CI, 62.8-95.8) at
15 years and 65.1% (95% CI, 18.3-89.7) at 24 years.
Thus, the merely symptomatic approach of long-term IS can be
beneficial in the short term, but it did not prevent disease
progression and development of complications in the majority
of the patients and it could have an impact on patients’ survival.Hematopoietic stem cell transplantation
Fifty-eight patients underwent HSCT. Seven patients required a
second transplant and 1 patient received 3 HSCTs. In
these patients, follow-up records refer to the last procedure. The
median follow-up was 2.7 years (range, 2 weeks-15 years).
The median age at onset for patients in this cohort was 1 month
(range, birth-1 year) and transplant was performed at a median
age of 1.4 years (range, 1 month-18.8 years), indicating that the
majority of the transplants were performed at early age and close
to disease onset (see Fig E1, A in this article’s Online Repository
at www.jacionline.org). Despite the short time frame between
onset and transplantation, 54 patients received IS prior to
transplantation. Disease manifestations improved before HSCT
in 27 of 54 patients, while 23 of 54 patients had partial or no
control of the autoimmune manifestations and 4 of 54 patients
could not be assessed for response. Application of the OI score
at the time of transplantation demonstrated a strong association
with outcome. The estimated overall survival after HSCT was
73.2% at 15 years, with significant differences for patients with
either low or high OI score, as described below.
HSCT characteristics and complications. The majority
of patients (33 of 58) received RIT (Table II; see also Table E1 in
this article’s Online Repository at www.jacionline.org for further
details about conditioning). Donor type included matched related
(31 of 58 patients), matched unrelated (21 of 58 patients),
haploidentical (5 of 58 patients, 3 of which had a/bT-cell
depletion), and other (1 mismatched related of 58 patients).
HSC sources included bone marrow (35 of 58 patients),
peripheral blood stem cells (12 of 58 patients), and cord blood
(13 of 58 patients). Antithymocyte globulin or alemtuzumab
were frequently used (49 of 58 patients). GvHD prophylaxis
mainly consisted of cyclosporine-A associated with
mycophenolate-mofetil or steroids. Hematological recovery was
obtained at a median of 16 days for neutrophils and 20 days for
TABLE II. Characteristics, outcomes, and complications of HSCT
No. patients Percent
Characteristics
Tot no. of patients 58
Age (y) at transplant, median (range) 1.4 (0.2-18.8)
Patients who received multiple transplants
2 HSCT 7
3 HSCT 1
Conditioning
Full 27 47
RIT 31 53
Donor-related; unrelated
Matched 10; 21 17; 36
1 MM 1; 13 2; 22
2 MM 0; 6 0; 10
3 MM 1; 1 2; 2
Haplo 5; 0 9; 0
HSC source
BM 35 60
PB 11 19
CB 12 21
Cell doses
BM (TNC 3 108/kg), median (range) 7.1 (0.01-91.3)
PB (CD34 3 106/kg), median (range) 11.4 (4.3-40)
CB (TNC 3 107/kg), median (range) 9.8 (0.6-42)
Serotherapy
ATG 22 38
Alm 27 46
None 9 16
GvHD prophylaxis
CSA 1 MMF 18 31
CSA 1 steroids 10 17
CSA 6 10
MTX 1 CSA (with or without short course of steroids) 8 14
MTX 1 FK506 1 steroids 7 12
Others 9 16
Bone marrow recovery
Neutrophils (days after HSCT), median (range) 16 (3-33)
Platelets (days after HSCT), median (range) 20 (5-114)
Immunoreconstitution
Patients with T cells > 1000/mmc at 1 y 22 of 33
Positive PHA response (months after HSCT), median (range) 14.5 (3-60)
Independence from IVIg substitution (months after HSCT), median (range) 7 (1-48)
Use of donor stem cell boost 3
Use of donor lymphocytes infusion 3
Complications
Transplant-related toxicity* 11 20
Infections 46 79
Tot GvHD, 21 36
aGvHD (grade I-IV) 19 33
aGvHD (grade III-IV) 9 16
cGvHD 6 10
No GvHD 37 64
Deaths 15 26
Alm, Alemtuzumab; aGvHD, acute graft-versus-host disease; ATG, antithymocyte globulin; BM, bone marrow; CB, cord blood; cGvHD, chronic graft-versus-host disease;
CSA, cyclosporine; FK506, tacrolimus; Full, full conditioning regimen; IVIg, intravenous immunoglobulin; MM, mismatch; MMF, mycophenolate mofetil; MTX, methotrexate;
PB, peripheral blood; PHA, phytohemagglutinine; TNC, total nucleated cells.
*Toxicity after HSCT consisted of mucositis, pneumonitis, posterior reversible encephalopathy, undefined hypertrophic cardiomyopathy, nephropathy, and hepatic sinusoidal
obstruction syndrome.
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cell reconstitution. At a median of 14.5 months, 20 of 29 patients
had positive proliferative response to mitogens. Independence
from IVIG was reached at a median of 7 months in 30 of 45 pa-
tients. Transplant-related toxicity was observed in 11 cases
(19%). Multiple infections were reported in 46 patients (85%).GvHD. Nineteen of the transplanted patients (33%)
experienced acute GvHD, which was of grade III to IV in 9
patients. Among patients surviving >100 days, 6 of 52 developed
chronic GvHD (10% of the transplanted patients). While not
statistically significant, the incidence of acute GvHD was higher
in patients who did not receive serotherapy (5 of 9; 55%)
Survival probability (%)
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FIG 4. Survival analysis of patients undergoing HSCT. Percentage of survival of patients undergoing HSCT
(n 5 58) according to conditioning (log-rank test, P 5 .234) (A), donor type (P 5 .886) (B), age at HSCT
(P 5 .359) (C), score pre-HSCT (P 5 .003) (D), score and conditioning (P 5 .010) (E), and score and age at
HSCT (P 5 .019) (F). A survival probability table accompanies those plots that show significant differences
(time points: 6 months, and 1, 3, 5, and 10 years). Full C, Full conditioning regimen; MMRD, mismatched
related donor; MMUCB, mismatched unrelated cord blood; MMUD, mismatched unrelated donor;
MSD, matched sibling donor; MUD, matched unrelated donor.
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FIG 5. Probability of survival and disease status after treatment. A, Survival analysis of IPEX patients
undergoing HSCT or IS (n 5 92, P 5 .055). B, Disease-free survival analysis of IPEX patients undergoing
IS or HSCT censored for deaths (n 5 81, P 5 .419).
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alemtuzumab (16 of 47; 34%), for 2 patients GvHD could not
be ascertained. Occurrence of acute GvHD was comparable
(P 5 .2362) in related (5 of 17; 29%) and unrelated (15 of 31;
48%) donor transplants. Overall, the incidence and severity of
GvHD for IPEX syndromewere similar to that described for other
primary immune deficiencies.18
Chimerism. Full donor peripheral blood chimerism was
detected in 31 of 53 patients evaluated for chimerism; 17 of them
were alive and in remission (or with T1D only). Among the
patients with full donor chimerism, 3 died and 11 had
autoimmune manifestations (or GvHD). Mixed chimerism was
detected in 18 of 53 patients and associated with disease
remission in 9 of 18 (Fig E1, B). Importantly, the Treg cells
were 100% of donor origin in 3 of 9 patients carrying mixed
chimerism in remission. Moreover, 4 of 18 patients with
mixed chimerism are alive with autoimmune manifestations
(Fig E1, C) and 5 of 18 patients have died—all but 1 of
infections, at different times post-HSCT (Fig E1, D). The
occurrence of mixed chimerism was not related to the use of
RIT and was also observed following fully myeloablative
conditioning. Overall, the data show similar proportion of
patients in remission among those with full (17 of 31, 54%) or
mixed (9 of 18, 50%) chimerism. In addition, graft failure was
observed in 4 of 53 patients (Fig E1, E). Two patients
experienced secondary graft failure between 3 and 6 months
posttransplantation, they are still alive but with disease relapse.
The other 2 patients are dead, 1 with primary graft failure and the
second with acute graft loss 40 days after transplant.
Survival after transplant. The estimated overall survival
rate for transplanted patients at 15 years was 73.2%. The majority
of deaths occurred in the first months after HSCT due to
infections. Multivariable analysis showed that the type of
conditioning, type of donor, and age at transplantation did not
significantly influence survival (Fig 4, A-C). In fact, the
pre-HSCTOI scorewas the only variable significantly influencing
survival after HSCT. Indeed, the probability of survival was
significantly lower in patients with a score between 3 and 5 as
compared to patients with an initial score between 0 and 2
(P 5 .002) (Fig 4, D). In addition, the combined analysis of thescore and of the conditioning regimen, showed that patients
with scores 0 to 2 had better survival independently of the
administration of full conditioning or RIT. Within the same
analysis, patients with scores 3 to 5 who received full
conditioning had better survival than the ones who received
RIT (Fig 4, E). Similarly, the OI score affected the survival
outcome among patients below or above 1 year of age, with
patients <1 year and high score performing significantly worse
(Fig 4, F). The majority of patients who were <1 year of age at
the time of HSCTwere also at or below the third centile for weight
(16 of 21 patients whose weight at transplantation was reported).
Among these patients, we further observed that the patients who
did not survive had lower weight and younger age, although the
number of events was not sufficient to perform a multivariable
analysis (see Fig E2, A and B in this article’s Online Repository
at www.jacionline.org). DFS analysis showed that the probability
of recurrent or new onset autoimmunity after transplantation was
not dependent on the conditioning administered (Fig E2, C) or
chimerism obtained after transplantation (Fig E2, D).
Multivariable analysis did not identify a variable significantly
affecting DFS after HSCT.
Comparison of outcomes between transplanted and
not transplanted patients. Survival rates at 15 years among
children undergoingHSCTwere lower, although not significantly,
as compared to those receiving chronic IS (73.2% vs 86.8%;
P 5 .055) (Fig 5, A). This difference is largely due to the high
mortality rate within 2.5 years following transplantation, with
up 15% of patients dying by the first 100 days and 25% by the first
2.5 years (Fig 5, A). Patients who survive over 2.5 years after
transplant do not show additional mortality up to 15 years later,
and their probability of survival remains constant, whereas that
of IS patients, who have a longer follow-up, drops as the disease
progresses and treatment complications increase with time
(survival rate at 24 years is 65.1%). Indeed, the survival of
patients receiving IS does not depend on the OI score pre-IS
but, in the long-term, a worsening of the OI score can negatively
influence the survival in these patients. Thus, the OI score post-IS
is significantly correlated with survival (P 5 .0444) (Fig 3, D).
The percentage of patients who completely resolved
autoimmunity (or had only T1D) was higher in alive transplanted
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(56% vs 36%, P5 .083). Similarly, the persistence or the onset of
new autoimmune manifestations (other than GvHD in
transplanted patients) was significantly lower in patients
surviving HSCT than under IS treatment (17% vs 51%,
P 5 .001) showing that IS does not prevent disease progression.
This latter conclusion is also supported by the DFS curve showing
a progressive reduction of DFS probability during IS. On the
contrary, DFS probability remains stable after the first 6 years
posttransplant (Fig 5, B).
We did not observe any significant correlation between disease
score or survival and the effect of the different mutations on the
FOXP3 protein, as predicted by PolyPhen-2 or PROVEAN, for
patients given either IS or HSCT (see Fig E3 in this article’s
Online Repository at www.jacionline.org).
In the entire cohort from 28% (under IS) to 31% (after HSCT) of
the patients experienced delayed neuromotor development or
needed a support teacher, despite comparable rates of patients
undergoing schooling/working activities adequate for age after
either therapeutic approach. Of note, a significant percentage of
children needed psychological support. Nutritional issues lead to a
frequent and prolonged use of feeding support in both categories.
In line with the outcome results, a significant percentage of
patients surviving HSCT considered this therapy efficacious. In
contrast, patients undergoing IS perceived an incomplete resolution
of the disease and complained about chronic medications, side
effects, and periodic follow-up (see Table E2 in this article’s
Online Repository at www.jacionline.org). This confirms that
patients surviving transplantation are less prone to disease
evolution and complications over time.DISCUSSION
The present retrospective study of IPEX patients provides an
informative comparison of the currently available therapeutic
options and their long-term outcome, together with a
comprehensive and updated view of the disease and its initial
presentation and progression. We demonstrate that IPEX patients
have similar overall survival, regardless of whether they receive
IS or HSCT, with a greater survival in the first years posttreatment
for the non-HSCT group. However, the DFS of HSCT patients
shows clear differences with stable resolution of autoimmunity as
compared to the persistent disease progression in the
nontransplanted IPEX patients. Therefore, the study highlights
the therapeutic limitations of the current immunosuppressive
regimens, although the use of rapamycin proved as the most
beneficial IS therapy11,19,20 and appears to be superior to
calcineurin inhibitors.13,21-24 Results from this study further
indicate that a better survival outcome after HSCT is significantly
affected by the patients’ pre-HSCT conditions, as defined by the
OI score we established. IPEX patients with low OI score, either
initially or after IS, had a survival advantage after HSCT. On the
contrary, IPEX patients with severe organ impairment (high OI
score) at HSCT had the lowest chance of survival even receiving
a RIT, suggesting that the clinical status is more important than
the conditioning regimens in the outcome of HSCT. Other
variables (ie, type of donor, stem cells source, and chimerism)
were not correlated with outcome, as was previously reported in
a small cohort of patients.25 In contrast though with this other
cohort,25 our data show that patients transplanted before 1 year
of age tended to have a lower survival (althoughwithout statisticalsignificance), which may reflect either a more severe disease
status or an increased sensitivity to conditioning agents. Overall,
these data point to the value of optimizing patient’s clinical
condition prior to HSCT and considering HSCT before disease
progression.
The majority of the patients in our study received a RIT,25-30
conditioning that is not always associated with mixed chimerism,
frequently observed in IPEX transplanted patients.13,14,21,25,26,30
Mixed rather than full donor chimerism did not affect DFS proba-
bility, as has been the case for other primary immunodeficiencies.31
Importantly, in a small number of IPEX patients14,30 with mixed
chimerism who achieved remission, all Treg cells were of donor
origin, indicating that the presence of functional Treg cells may
suffice to control autoimmunity and supporting the importance
of evaluating lineage-specific chimerism.
In addition to the analysis of outcomes, results from the present
data collection strengthen the notion that the disease onset is
usually early, with half of the patients presenting within the first
month of life. We show that enteropathy, T1D, and eczema are the
initial symptoms, especially in neonates, while in the later onset
patients, failure to thrive becomes a predominant symptom at
presentation. With the increasing number of IPEX patients
diagnosed over time, a group of asymptomatic patients or patients
initially presenting with only T1D have been identified. With
disease progression, multiple other autoimmune symptoms arise
with blood, kidney, and liver frequently targeted. Unexpectedly,
neurological impairment, respiratory involvement, and cardiac
complications have been often observed, though their autoimmune
origin rather than toxic or infectious pathogenesis remains unclear
and should be investigated in a prospective study. As has been
previously suggested,9,32 it is difficult to correlate the site of muta-
tion with disease course or outcome. For example, mutations in the
FKH domain, required for FOXP3 nuclear localization and DNA
binding, correlated with the earliest onset, while there was no
association between type of mutation and outcome. Furthermore,
the same genotype can present with variable phenotypes. Indeed,
asymptomatic children carrying the samemutation of their affected
siblings have been recently published15 and herein reported
(siblings carrying the c.1190 G>A mutation). Future prospective
studies should be considered to better understand the functional
effects of each FOXP3 mutation, at disease onset and during
disease course. Similarly, future studies should focus on evaluating
the effect of different immunosuppressive regimens on the
regulation of FOXP3 expression and its epigenetic modification
such as demethylation at the Treg cell–specific demethylated
region, which is essential to maintain Treg cells’ identity.33,34
Overall, this retrospective study instructs that rapamycin
should be the preferred choice as IS treatment, while HSCT
should be considered in patients with low OI score and stable
clinical conditions. In conclusion, our comprehensive description
of the natural history of IPEX and comparison of the effects of IS
and HSCTmay assist in determining therapeutic choices for these
complex patients.
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d Pretreatment organ impairment score in IPEX best pre-
dicts overall survival after HSCT.
d HSCT and IS recipients experience similar overall sur-
vival, but those receiving HSCT demonstrate higher rates
of disease-free survival.REFERENCES
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FIG E1. Age distribution and chimerism. A, Histogram distribution of number of patients undergoing HSCT
from 0 to 20 years grouped by age at onset. Percentage of donor chimerism at different time points in pa-
tients who experienced mixed chimerism with remission (B), mixed chimerism with persistence of autoim-
munity (C), death (D), and graft failure (E).
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FIG E2. Influence of age, weight, conditioning, and chimerism on HSCT outcome. Association of survival
with score and age at HSCT (n5 25) (A) or weight at HSCT (n5 21) (B) among patients undergoing HSCT at
1 year of age or below. Bars show mean 6 SD. DFS curve, of patients who underwent HSCT according to
type of conditioning (n5 50, P5 .712) (C) and chimerism (n5 44, P5 .899) (D). Patients who died early after
transplant or without any autoimmunity were excluded from this analysis.
J ALLERGY CLIN IMMUNOL
VOLUME 141, NUMBER 3
BARZAGHI ET AL 1049.e2
ALIVE DEAD
-25
-20
-15
-10
-5
0
5
Pr
ov
ea
n
Sc
or
e
0-2 3-5
0.0
0.5
1.0
1.5
Po
ly
Ph
en
Sc
or
e
0-2 3-5
-25
-20
-15
-10
-5
0
5
Pr
ov
ea
n
Sc
or
e
ALIVE DEAD
0.0
0.5
1.0
1.5
Po
ly
Ph
en
Sc
or
e
A B
C D
FIG E3. Predicted mutation effect on protein structure and function. Summary statistics of protein effect
score predicted by PROVEAN protein web tool (score: -30 to 0, deleterious to neutral) between alive and
dead patients (A) and among patients with different scores pre-HSCT (B). Summary statistics of protein ef-
fect score predicted by PolyPhen-2 algorithm (score: 0-1, benign to damaging) between alive and dead pa-
tients (C) and among patients with different scores pre-HSCT (D). No significant differences were found
between the groups analyzed. Each point represents a patient, the column height indicates the median
score, and the error bars represent the SD.
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TABLE E1. Conditioning regimens
Conditioning Full (tot 29) RIT (tot 29)
Bu 1 Flu
1 Alm 2 3
1 ATG 1 4
Bu 1 Cy 2 —
1 Alm 3 —
1 ATG 4 —
Treo 1 Flu
1 Alm 1 4
1 ATG — 2
Mel 1 Flu
1 Alm — 8
1 ATG — 2
Treo 1 Flu 1 Thio
1 Alm 2 —
1 ATG 3 —
Bu 1 Flu 1 Cy (6TBI)
1 ATG 6 —
Others 5 6
Alm, Alemtuzumab; ATG, anti-thymocyte globulin; Bu, busulfan; Cy, cyclophosphamide;
Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; Thio, thiotepa;
Treo, treosulfan.
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TABLE E2. Summary quality of life questionnaire
HSCT (n 5 42) IS (n 5 26) P value
Age (y), median (range) 10 (2-24.4) 13.25 (0.3-28.8)
Questions n/n (%) n/n (%)
Q1. Adequate age schooling/working activity 30/38 (79) 18/23 (78) NS
Q2. Regular schooling/working activity 28/35 (80) 16/23 (69) NS
Q3. Abnormal neuromotor development 11/39 (28) 8/25 (32) NS
Q4. Support teacher 9/34 (26) 8/23 (35) NS
Q5. Normal nutrition 33/41 (80) 16/25 (64) NS
Q6. Normal relationships 33/38 (87) 16/22 (73) NS
Q7. Psychological support 7/37 (19) 6/24 (25) NS
Q8. Considers the therapy efficacious 33/36 (92) 15/22 (68) .052
Q9. Complains about medicines 2/34 (6) 12/33 (36) <.001
Q10. Complains about side effects 2/35 (6) 8/23 (35) .012
Q11. Complains about follow-up 4/36 (11) 11/22 (50) .002
NS, Not significant.
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